AP505 / Tasly, AP Biosciences - LARVOL DELTA

A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Tasly Biopharmaceuticals Co., Ltd.

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=35 | Active, not recruiting | Sponsor: AP Biosciences Inc.

Metastases • New P1 trial • Oncology • Solid Tumor

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Tasly Biopharmaceuticals Co., Ltd.

Metastases • New P2 trial • Breast Cancer • Cervical Cancer • Colorectal Cancer • Hepatocellular Cancer • Hepatology • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=68 | Not yet recruiting | Sponsor: Tasly Biopharmaceuticals Co., Ltd.

New P1 trial • Oncology • Solid Tumor